Grant of Warrants to Board Members, Management and Employees in Genmab A/S

Copenhagen, Denmark; June 27, 2007 - On a board meeting held on June 27, 2007 in
Genmab A/S (CSE: GEN) the board of directors decided to issue 826,045 warrants  
to members of the board of directors, managers and employees of the company and 
the company's subsidiaries.                                                     
                                                                                
The exercise price for each warrant is DKK 352.50. Each warrant entitles the    
owner to subscribe one share of nominally DKK 1. On the basis of an exercise    
price of DKK 352.50 and by application of the Black-Scholes formula, the average
value of each warrant can be calculated as DKK 143.57 based on an interest rate 
of 4.30% and the historical volatility of Genmab A/S shares calculated at       
37.10%.                                                                         
                                                                                
The warrants vest in blocks of 25% one, two, three and four years after the     
grant date, and all warrants expire at the tenth anniversary of the grant date. 
The new warrants were granted pursuant to the warrant plan adopted by the board 
of directors on August 3, 2004. Information concerning Genmab's warrant schemes 
can be found on www.genmab.com under the heading ‘warrant scheme.'              

In accordance with Section 28a of the Danish Securities Trading Act the company 
hereby makes public that the following persons received the following number of 
warrants:                                                                       

Members of the Board:                                                           
Michael B. Widmer received 30,000 warrants.                                     
Anders Gersel Pedersen received 15,000 warrants.                                
Karsten Havkrog Pedersen received 15,000 warrants.                              
Ernst H. Schweizer received 15,000 warrants.                                    
Burton G. Malkiel received 15,000 warrants.                                     
Hans Henrik Munch-Jensen received 15,000 warrants.                              

Members of the Management:                                                      
Lisa N. Drakeman received 200,000 warrants.                                     
Jan G. J. van de Winkel received 100,000 warrants.                              
Claus Juan Møller-San Pedro received 100,000 warrants.                          
Bo Kruse received 75,000 warrants.                                              

About Genmab A/S                                                                
Genmab A/S is a biotechnology company that creates and develops human antibodies
for the treatment of life-threatening and debilitating diseases. Genmab has     
numerous products in development to treat cancer, infectious disease, rheumatoid
arthritis and other inflammatory conditions, and intends to continue assembling 
a broad portfolio of new therapeutic products. In addition, Genmab has developed
UniBody(TM), a new proprietary technology that creates a stable, smaller        
antibody format.  Genmab has operations in Europe and the US. For more          
information about Genmab, visit www.genmab.com.                                 

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 30/2007                                              

###